Clinical Trial

Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Trial Details
NCT Number NCT07297745
Lead Sponsor Changi General Hospital
Collaborators: Singapore General Hospital, Sengkang General Hospital, National University Hospital, Singapore
Conditions Hyperaldosteronism; Primary, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Enrollment 120 participants
Start Date 2026-01-15
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-09